Quantcast
Last updated on April 24, 2014 at 12:48 EDT

Latest Immunosuppressive agents Stories

2008-09-18 15:00:12

New data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis (RRMS) demonstrated a significant reduction in the mean number of gadolinium-enhancing (GdE) lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose. In RRMS patients who switched from placebo to laquinimod, 52 percent reduction in the mean number of GdE lesions was observed (p less than 0.0007). The reduction was significant for...

2008-07-16 09:01:19

Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial. Bravo is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex. The Bravo trial, which was initiated in April, 2008, aims to enroll approximately 1,200...

2008-07-16 03:00:16

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced today that patients are being enrolled for the BRAVO Phase III pivotal trial. BRAVO is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex(R). The BRAVO trial, which was initiated in April this...

2008-06-20 00:00:28

Tomorrow's issue of the scientific journal The Lancet, Volume 371, Issue 9630, includes an article covering Active Biotech's (OMX Nordic: ACTI) and Teva Pharmaceutical Industries Ltd's novel oral MS drug laquinimod. The article, entitled "Effect of Laquinimod on MRI-monitored disease activity in patients with RRMS: a multicenter, randomized, double-blind, placebo-controlled phase IIb study", will be available on www.thelancet.com. Laquinimod is currently in global clinical Phase III trials in...

2006-08-31 11:20:00

By Megan Rauscher NEW YORK -- In patients with rheumatoid arthritis, use of disease-modifying antirheumatic drugs, or DMARDs, seems to lower the increased risk of cardiovascular disease associated with rheumatoid arthritis, research suggests. In a nested case-control analysis within a cohort of RA patients, the rate of acute heart attack was significantly lower in current users of any DMARD, including methotrexate, leflunomide (Arava), and other traditional DMARDs, but not with current use of...

2006-04-05 16:15:00

By Deena Beasley LOS ANGELES (Reuters) - A high dose of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone is more effective at limiting relapses and brain lesions than the standard dose, without more side effects, researchers said on Wednesday. "For some people a higher dose may work better," said Dr. Jeffrey Cohen of the Cleveland Clinic's MS research center and lead investigator of a small nine-month trial comparing the two doses. The study, funded by Israel-based Teva,...

2006-03-16 13:20:00

NEW YORK (Reuters Health) - Patients with rheumatoid arthritis who are treated with low-dose prednisone have an increased risk of coming down with pneumonia, a new study indicates. However, the findings also show that most other drugs used to treat arthritis don't have this drawback. Prednisone, a steroid, tends suppresses the immune system and at high enough doses this could increase the chances of infection. "If the results of this study are correct, they may undermine the current belief...

2006-03-02 16:40:10

NEW YORK (Reuters Health) - Even if an initial course of methotrexate for the treatment of rheumatoid arthritis (RA) gives disappointing results, persistence may pay off. A second course may be more successful, researchers report. As they note in the journal Arthritis Research & Therapy, many patients continue to have active disease in spite of intensive therapy with disease-modifying antirheumatic drugs (DMARDs). Dr. Daniel Aletaha, from the National Institute of Arthritis and...

2006-01-17 12:17:17

NEW YORK (Reuters Health) - While pimecrolimus cream can be very effective for treating atopic dermatitis (often called eczema), there has been concern about infections because it is an immune suppressing drug -- but that seems to be unfounded. A review of clinical trials that tested pimecrolimus cream in infants with atopic dermatitis indicates that it is not associated with a higher rate of infections, other adverse events or generalized immune suppression, investigators report in...